Clearmind Medicine Inc., a clinical-stage biotech company, has announced the publication of a Japanese Patent Application for its proprietary compositions of MEAI (5-Methoxy-2-aminoindan), a non-hallucinogenic molecule designed to treat depression. The advance strengthens Clearmind’s intellectual property portfolio, which already includes multiple granted patents and applications worldwide.
Depression remains one of the leading causes of disability worldwide. Current treatments, primarily selective serotonin reuptake inhibitors (SSRIs) and other conventional antidepressants, often come with limitations including delayed onset of action, side effects, and high rates of treatment resistance. MEAI is designed to offer a safer, more accessible alternative to traditional antidepressants and emerging psychedelic-based therapies.
The market opportunity is substantial. The global market for anxiety and depression treatments is experiencing steady growth, estimated at approximately $16–22.65 billion in 2025, with projections reaching $19–30 billion by 2030–2031, driven by rising mental health awareness, increasing prevalence of disorders, and demand for innovative therapies. The broader behavioral and mental health market is valued at around $185 billion in 2025 and expected to approach $350 billion by 2035.
Japan represents a particularly important market, where mental health challenges are pronounced due to societal factors such as work-related stress. The country has approximately 3 million diagnosed cases of Major Depressive Disorder. Clearmind’s IP portfolio now spans multiple jurisdictions, consisting of nineteen patent families with 31 granted patents.
Clearmind continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic disorders such as weight loss, and various other mental disorders. The company is a clinical-stage neuroplastogens pharmaceutical biotech focused on the discovery and development of non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines. Clearmind shares are listed for trading on Nasdaq under the symbol “CMND.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/gnwcq-2026-5-29-clearmind-medicine-advances-global-intellectual-property-portfolio-with-japanese-patent-filing-for-innovative-psychedelic-based-depression-treatment